David MacNaughtan (Sagard Holdings)
Royalty Pharma gets more competition as a private equity firm launches $725M royalty-buying fund
Pablo’s got some peers.
Twenty-five years after Mexican billionaire Pablo Legorreta started buying up future royalties on approved drugs — and eight months after he …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.